Spots Global Cancer Trial Database for Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
Official Title: A Phase 1, Double-blind, Placebo-controled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPI-1005 (Ebselen)in Healthy Adult Subjects
Study ID: NCT01452607
Study Description
Brief Summary: A study to determine the safety, tolerability, and pharmacokinetics of SPI-1005 capsules in healthy adults.
Detailed Description:
Keywords
Eligibility
Minimum Age: 19 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
MDS Pharma Services, Lincoln, Nebraska, United States
Contact Details
Name: James C. Kisicki, M.D.
Affiliation: MDS Pharma Services
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
